Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial

Table 1 Demographic and baseline characteristics of the study population in the two groups, n (%)

	Placebo group	rhBNP group	P value
Age (mean ± SD)	75.42 ± 12.88	75.58 ± 12.69	0.943
Male	49 (74.2)	43 (66.2)	0.311
Hypertension	36 (54.5)	32 (49.2)	0.543
Diabetes	7 (10.6)	8 (12.3)	0.760
Hyperlipemia	46 (69.7)	43 (66.2)	0.664
Smoking	18 (27.3)	15 (23.1)	0.580
Killip score (mean ± SD)	2.15 ± 0.52	2.09 ± 0.49	0.498
B natriuretic peptide [median (Q1, Q3)]	69 (18384)	78 (35621)	0.752
Troponin I (ng/L, mean ± SD)	55.18 ± 10.22	53.29 ± 11.08	0.312
Treatment			0.635
Coronary arteriography	9 (13.6)	11 (16.9)	0.759
PCI	57 (86.4)	54 (83.1)	0.787
Lesion location
Left main	7 (10.6)	5 (7.7)	0.563
Left anterior descending branch	30 (45.5)	34 (52.3)	0.433
Left circumflex branch	12 (18.2)	9 (13.8)	0.499
Right coronary artery	17 (25.7)	17 (26.2)	0.959
LVEF (%, mean ± SD)	59.47 ± 3.29	60.16 ± 3.15	0.223
Contrast agent dosage [mL, median (Q1, Q3)]	135 (60175)	130 (70160)	0.912
Intro-operative IABP	7 (10.6)	8 (12.3)	0.760
Hospitalized
ACEI/ARB	35 (53.0)	32 (48.5)	0.664
Receptor antagonist	52 (78.8)	56 (86.2)	0.268
Calcium channel blocker	29 (43.9)	27 (41.5)	0.781
Natriuretic agent	22 (33.3)	25 (38.5)	0.541

rhBNP: Recombinant human brain natriuretic peptide; PCI: Percutaneous coronary intervention.